<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NIZATIDINE- nizatidine capsule </strong><br>Genpharm Inc.<br></p></div>
<h1>NIZATDINE CAPSULES USP<br>Rx only</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_F71EED81-1DD6-47BD-A9B3-81EFDF4F0F34"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Nizatidine, USP is a histamine H<span class="Sub">2</span>-receptor antagonist. Chemically, it is N– [2-[ [ [2-[(Dimethylamino)methyl]-4-thia-zolyl]methyl]thio]ethyl] -N’-methyl-2-nitro-1, 1-ethenediamine. The structural formula is as follows:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9A148542-E478-422A-B8FB-88047C30534B&amp;name=nizatidine-capsul-01.jpg"></div>
<p>Nizatidine</p>
<p>Nizatidine has the molecular formula C<span class="Sub">12</span>H<span class="Sub">21</span>N<span class="Sub">5</span>O<span class="Sub">2</span>S<span class="Sub">2</span> representing a molecular weight of 331.46. It is an off-white to buff crystalline solid that is soluble in water. Nizatidine has a bitter taste and mild sulfur-like odor. Nizatidine Capsules, USP, for oral administration, contain 150 mg or 300 mg nizatidine and the following inactive ingredients: croscarmellose sodium, gelatin, magnesium stearate, pregelatinized starch, red iron oxide, talc, titanium dioxide, and yellow iron oxide. The150 mg capsule also contains D&amp;C Yellow #10 and FD&amp;C Red #40.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_BDD96CD4-0A9E-45CB-BA6D-06375DE75F52"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H<span class="Sub">2</span>-receptors, particularly those in the gastric parietal cells.</p>
<p><span class="Bold"><span class="Emphasis">Antisecretory Activity</span></span></p>
<p>EFFECTS ON ACID SECRETION</p>
<p>Nizatidine significantly inhibited nocturnal gastric acid secretion for up to 12 hours. Nizatidine also significantly inhibited gastric acid secretion stimulated by food, caffeine, betazole, and pentagastrin (Table 1).</p>
<p>Table 1</p>
<p>Effect of Oral Nizatidine on Gastric Acid Secretion</p>
<a name="ID_1102EF7E-A5D1-4DCD-B85D-35434C56889F"></a><table border="single" frame="box" width="405">
<col width="17.778%">
<col width="17.778%">
<col width="13.333%">
<col width="11.111%">
<col width="13.333%">
<col width="13.333%">
<col width="13.333%">
<tbody class="Headless">
<tr class="First">
<td align="center" rowspan="2" valign="top"></td>
<td align="center" rowspan="2" valign="top">Time After Dose (h)</td>
<td align="center" colspan="5" valign="top">
<p class="First">% Inhibition of Gastric Acid Output by</p>Dose (mg)</td>
</tr>
<tr>
<td align="center" valign="top">20-50</td>
<td align="center" valign="top">75</td>
<td align="center" valign="top">100</td>
<td align="center" valign="top">150</td>
<td align="center" valign="top">300</td>
</tr>
<tr>
<td align="center" valign="top">Nocturnal</td>
<td align="center" valign="top">Up to 10</td>
<td align="center" valign="top">57</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">73</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">90</td>
</tr>
<tr>
<td align="center" valign="top">Betazole</td>
<td align="center" valign="top">Up to 3</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">93</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">100</td>
<td align="center" valign="top">99</td>
</tr>
<tr>
<td align="center" valign="top">Pentagastrin</td>
<td align="center" valign="top">Up to 6</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">25</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">64</td>
<td align="center" valign="top">67</td>
</tr>
<tr>
<td align="center" valign="top">Meal</td>
<td align="center" valign="top">Up to 4</td>
<td align="center" valign="top">41</td>
<td align="center" valign="top">64</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">98</td>
<td align="center" valign="top">97</td>
</tr>
<tr>
<td align="center" valign="top">Caffeine</td>
<td align="center" valign="top">Up to 3</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">73</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">85</td>
<td align="center" valign="top">96</td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>EFFECTS ON OTHER GASTROINTESTINAL SECRETIONS</p>
<p><span class="Italics">Pepsin</span></p>
<p>Oral administration of 75 to 300 mg of nizatidine did not affect pepsin activity in gastric secretions. Total pepsin output was reduced in proportion to the reduced volume of gastric secretions.</p>
<p><span class="Italics">Intrinsic Factor</span></p>
<p>Oral administration of 75 to 300 mg of nizatidine increased betazole-stimulated secretion of intrinsic factor.</p>
<p><span class="Italics">Serum Gastrin</span></p>
<p>Nizatidine had no effect on basal serum gastrin. No rebound of gastrin secretion was observed when food was ingested 12 hours after administration of nizatidine.</p>
<p>OTHER PHARMACOLOGIC ACTIONS</p>
<p>A. Hormones: Nizatidine was not shown to affect the serum concentrations of gonadotropins, prolactin, growth hormone, antidiuretic hormone, cortisol, triiodothyronine, thyroxin, testosterone, 5α-dihydrotestosterone, androstenedione, or estradiol.</p>
<p>B. Nizatidine had no demonstrable antiandrogenic action.</p>
<p>PHARMACOKINETICS</p>
<p>The absolute oral bioavailability of nizatidine exceeds 70%. Peak plasma concentrations (700 to 1,800 mcg/L for a 150 mg dose and 1,400 to 3,600 mcg/L for a 300 mg dose) occur from 0.5 to 3 hours following the dose. A concentration of 1,000 mcg/L is equivalent to 3 mcmol/L; a dose of 300 mg is equivalent to 905 mcmoles. Plasma concentrations 12 hours after administration are less than 10 mcg/L. The elimination half-life is 1 to 2 hours, plasma clearance is 40 to 60 L/h, and the volume of distribution is 0.8 to 1.5 L/kg. Because of the short half-life and rapid clearance of nizatidine, accumulation of the drug would not be expected in individuals with normal renal function who take either 300 mg once daily at bedtime or 150 mg twice daily. Nizatidine exhibits dose proportionality over the recommended dose range.</p>
<p>The oral bioavailability of nizatidine is unaffected by concomitant ingestion of propantheline. Antacids consisting of aluminum and magnesium hydroxides with simethicone decrease the absorption of nizatidine by about 10%. With food, the AUC and C<span class="Sub">max</span> increase by approximately 10%.</p>
<p>In humans, less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H<span class="Sub">2</span>-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).</p>
<p>More than 90% of an oral dose of nizatidine is excreted in the urine within 12 hours. About 60% of an oral dose is excreted as unchanged drug. Renal clearance is about 500 mL/min, which indicates excretion by active tubular secretion. Less than 6% of an administered dose is eliminated in the feces.</p>
<p>Moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> significantly prolongs the half-life and decreases the clearance of nizatidine. In individuals who are functionally anephric, the half-life is 3.5 to 11 hours, and the plasma clearance is 7 to 14 L/h. To avoid accumulation of the drug in individuals with clinically significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the amount and/or frequency of doses of nizatidine should be reduced in proportion to the severity of dysfunction (see <span class="Bold"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span>).</p>
<p>Approximately 35% of nizatidine is bound to plasma protein, mainly to α<span class="Sub">1</span>-acid glycoprotein. Warfarin, diazepam, acetaminophen, propantheline, phenobarbital, and propranolol did not affect plasma protein binding of nizatidine <span class="Italics">in vitro</span>.</p>
<p><span class="Bold"><span class="Emphasis">Clinical Trials</span></span></p>
<p>ACTIVE <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">DUODENAL ULCER</span></p>
<p>In multicenter, double-blind, placebo-controlled studies in the United States, endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> healed more rapidly following administration of nizatidine, 300 mg h.s. or 150 mg b.i.d., than with placebo (Table 2). Lower doses, such as 100 mg h.s., had slightly lower effectiveness.</p>
<p>Table 2</p>
<a name="ID_9E5F9C01-A34B-4AD5-9A5B-7F9DDBE5FE7E"></a><table border="single" frame="box" width="441">
<col width="12.018%">
<col width="12.472%">
<col width="20.408%">
<col width="10.204%">
<col width="18.367%">
<col width="10.204%">
<col width="16.327%">
<tbody class="Headless">
<tr class="First">
<td align="center" rowspan="4" valign="top"></td>
<td align="center" colspan="4" valign="top">Healing Response of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> to Nizatidine</td>
<td align="center" colspan="2" valign="top"></td>
</tr>
<tr>
<td align="center" colspan="4" valign="top">Nizatidine</td>
<td align="center" colspan="2" valign="top">Placebo</td>
</tr>
<tr>
<td align="center" colspan="2" valign="top">300 mg h.s.</td>
<td align="center" colspan="2" valign="top">150 mg b.i.d.</td>
<td align="center" rowspan="2" valign="top">
<p class="First">Number</p>Entered</td>
<td align="center" rowspan="2" valign="top">
<p class="First">Healed/</p>Evaluable</td>
</tr>
<tr>
<td align="center" valign="top">
<p class="First">Number</p>Entered</td>
<td align="center" valign="top">
<p class="First">Healed/</p>Evaluable</td>
<td align="center" valign="top">
<p class="First">Number</p>Entered</td>
<td align="center" valign="top">
<p class="First">Healed/</p>Evaluable</td>
</tr>
<tr>
<td align="center" valign="top">STUDY 1</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Week 2</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">276</td>
<td align="center" valign="top">93/265 (35%)*</td>
<td align="center" valign="top">279</td>
<td align="center" valign="top">55/260 (21%)</td>
</tr>
<tr>
<td align="center" valign="top">Week 4</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">198/259 (76%)*</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">95/243 (39%)</td>
</tr>
<tr>
<td align="center" valign="top">STUDY 2</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Week 2</td>
<td align="center" valign="top">108</td>
<td align="center" valign="top">24/103 (23%)*</td>
<td align="center" valign="top">106</td>
<td align="center" valign="top">27/101 (27%)*</td>
<td align="center" valign="top">101</td>
<td align="center" valign="top">9/93 (10%)</td>
</tr>
<tr>
<td align="center" valign="top">Week 4</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">65/97 (67%)*</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">66/97 (68%)*</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">24/84 (29%)</td>
</tr>
<tr>
<td align="center" valign="top">STUDY 3</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">Week 2</td>
<td align="center" valign="top">92</td>
<td align="center" valign="top">22/90 (24%)†</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">98</td>
<td align="center" valign="top">13/92 (14%)</td>
</tr>
<tr>
<td align="center" valign="top">Week 4</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">52/85 (61%)*</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">29/88 (33%)</td>
</tr>
<tr>
<td align="center" valign="top">Week 8</td>
<td align="center" valign="top"></td>
<td align="center" valign="top">68/83 (82%)*</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">39/79 (49%)</td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>†P&lt;0.05 as compared with placebo.</p>
<p>MAINTENANCE OF HEALED <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">DUODENAL ULCER</span></p>
<p>Treatment with a reduced dose of nizatidine has been shown to be effective as maintenance therapy following healing of active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. In multicenter, double-blind, placebocontrolled studies conducted in the United States, 150 mg of nizatidine taken at bedtime resulted in a significantly lower incidence of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence in patients treated for up to 1 year (Table 3).</p>
<p>Table 3</p>
<p>Percentage of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> Recurring by 3, 6, and 12 Months in Double-Blind Studies Conducted in the United States</p>
<a name="ID_11938F76-A5FE-4E41-B07E-C368C2C377E4"></a><table border="single" frame="box" width="351">
<col width="30.769%">
<col width="35.897%">
<col width="33.333%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top">Month</td>
<td align="center" valign="top">Nizatidine, 150 mg h.s.</td>
<td align="center" valign="top">Placebo</td>
</tr>
<tr>
<td align="center" valign="top">3</td>
<td align="center" valign="top">13% (28/208)*</td>
<td align="center" valign="top">40% (82/204)</td>
</tr>
<tr>
<td align="center" valign="top">6</td>
<td align="center" valign="top">24% (45/188)*</td>
<td align="center" valign="top">57% (106/187)</td>
</tr>
<tr class="Last">
<td align="center" valign="top">12</td>
<td align="center" valign="top">34% (57/166)*</td>
<td align="center" valign="top">64% (112/175)</td>
</tr>
</tbody>
</table>
<p><span class="Italics">* P </span>&lt;0.001 as compared with placebo.</p>
<p><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GASTROESOPHAGEAL REFLUX DISEASE</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</p>
<p>In 2 multicenter, double-blind, placebo-controlled clinical trials performed in the United States and Canada, nizatidine was more effective than placebo in improving endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and in healing erosive and ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
<p>In patients with erosive or ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, 150 mg b.i.d. of nizatidine given to 88 patients compared with placebo in 98 patients in Study 1 yielded a higher healing rate at 3 weeks (16% vs 7%) and at 6 weeks (32% vs 16%, <span class="Italics">P</span>&lt;0.05). Of 99 patients on nizatidine and 94 patients on placebo, Study 2 at the same dosage yielded similar results at 6 weeks (21% vs 11%,<span class="Italics"> P</span>&lt; 0.05) and at 12 weeks (29% vs 13%,<span class="Italics"> P</span>&lt;0.01)<span class="Italics">.</span></p>
<p>In addition, relief of associated <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> was greater in patients treated with nizatidine. Patients treated with nizatidine consumed fewer antacids than did patients treated with placebo.</p>
<p>ACTIVE BENIGN <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">GASTRIC ULCER</span></p>
<p>In a multicenter, double-blind, placebo-controlled study conducted in the United States and Canada, endoscopically diagnosed benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> healed significantly more rapidly following administration of nizatidine than of placebo (Table 4).</p>
<p>Table 4</p>
<a name="ID_EDA17469-F2A4-46B2-9F34-5AEEEB3759BC"></a><table border="single" frame="box" width="387">
<col width="13.178%">
<col width="28.682%">
<col width="27.907%">
<col width="30.233%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top">Week</td>
<td align="center" valign="top">Treatment</td>
<td align="center" valign="top">Healing Rate</td>
<td align="center" valign="top">vs. Placebo p-value*</td>
</tr>
<tr>
<td align="center" valign="top">4</td>
<td align="center" valign="top">Niz 300 mg h.s.</td>
<td align="center" valign="top">52/153 (34%)</td>
<td align="center" valign="top">0.342</td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="center" valign="top">Niz 150 mg b.i.d.</td>
<td align="center" valign="top">65/151 (43%)</td>
<td align="center" valign="top">0.022</td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="center" valign="top">Placebo</td>
<td align="center" valign="top">48/151 (32%)</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">8</td>
<td align="center" valign="top">Niz 300 mg h.s.</td>
<td align="center" valign="top">99/153 (65%)</td>
<td align="center" valign="top">0.011</td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="center" valign="top">Niz 150 mg b.i.d.</td>
<td align="center" valign="top">105/151 (70%)</td>
<td align="center" valign="top">&lt;0.001</td>
</tr>
<tr class="Last">
<td align="center" valign="top"></td>
<td align="center" valign="top">Placebo</td>
<td align="center" valign="top">78/151 (52%)</td>
<td align="center" valign="top"></td>
</tr>
</tbody>
</table>
<p>* P-values are one-sided, obtained by Chi-square test, and not adjusted for multiple comparisons.</p>
<p>In a multicenter, double-blind, comparator-controlled study in Europe, healing rates for patients receiving nizatidine (300 mg h.s. or 150 mg b.i.d.) were equivalent to rates for patients receiving a comparator drug, and statistically superior to historical placebo control rates.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_4164A075-D73D-4146-BC5B-E5C6F617233F"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Nizatidine is indicated for up to 8 weeks for the treatment of active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>. In most patients, the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> will heal within 4 weeks.</p>
<p>Nizatidine is indicated for maintenance therapy for <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> patients, at a reduced dosage of 150 mg h.s. after healing of an active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>. The consequences of continuous therapy with nizatidine for longer than 1 year are not known.</p>
<p>Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, including erosive and ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, and associated <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> due to <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>.</p>
<p>Nizatidine is indicated for up to 8 weeks for the treatment of active benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_3B943988-CDA1-4DE7-B715-712AE6D138F2"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Nizatidine is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug. Because crosssensitivity in this class of compounds has been observed, H<span class="Sub">2</span>-receptor antagonists, including nizatidine, should not be administered to patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other H<span class="Sub">2</span>-receptor antagonists.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_4654DD2B-0E95-491B-A049-9397510DA6B7"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_34CB0120-F913-408E-9A2D-B19EF24470DB"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Symptomatic response to nizatidine therapy does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</p>
<p>Because nizatidine is excreted primarily by the kidney, dosage should be reduced in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (see <span class="Bold"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span>).</p>
<p>Pharmacokinetic studies in patients with <span class="product-label-link" type="condition" conceptid="196455" conceptname="Hepatorenal syndrome">hepatorenal syndrome</span> have not been done. Part of the dose of nizatidine is metabolized in the liver. In patients with normal renal function and uncomplicated hepatic dysfunction, the disposition of nizatidine is similar to that in normal subjects.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_ID_02074C17-FCA3-4939-9B84-C6C545646D6B"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory tests</h2>
<p class="First">False-positive tests for urobilinogen with Multistix® may occur during therapy with nizatidine.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_23381DC9-B620-4BAF-A486-5F2557AC864D"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin. Nizatidine does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system; therefore, drug interactions mediated by inhibition of hepatic metabolism are not expected to occur. In patients given very high doses (3,900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_83E64290-F4C8-450D-8FC2-2BDD82266054"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">A 2-year oral carcinogenicity study in rats with doses as high as 500 mg/kg/day (about 80 times the recommended daily therapeutic dose) showed no evidence of a carcinogenic effect. There was a dose-related increase in the density of enterochromaffin-like (ECL) cells in the gastric oxyntic mucosa. In a 2-year study in mice, there was no evidence of a carcinogenic effect in male mice; although hyperplastic <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> of the liver were increased in the high-dose males as compared with placebo. Female mice given the high dose of nizatidine (2,000 mg/kg/day, about 330 times the human dose) showed marginally statistically significant increases in hepatic carcinoma and <span class="product-label-link" type="condition" conceptid="4047301" conceptname="Focal nodular hyperplasia">hepatic nodular hyperplasia</span> with no numerical increase seen in any of the other dose groups. The rate of hepatic carcinoma in the high-dose animals was within the historical control limits seen for the <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of mice used. The female mice were given a dose larger than the maximum tolerated dose, as indicated by excessive (30%) weight decrement as compared with concurrent controls and evidence of mild <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> (transaminase elevations). The occurrence of a marginal finding at high dose only in animals given an excessive and somewhat hepatotoxic dose, with no evidence of a carcinogenic effect in rats, male mice, and female mice (given up to 360 mg/kg/day, about 60 times the human dose), and a negative mutagenicity battery are not considered evidence of a carcinogenic potential for nizatidine.</p>
<p>Nizatidine was not mutagenic in a battery of tests performed to evaluate its potential genetic toxicity, including bacterial mutation tests, unscheduled DNA synthesis, sister chromatid exchange, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, chromosome aberration tests, and a micronucleus test.</p>
<p>In a 2-generation, perinatal and postnatal fertility study in rats, doses of nizatidine up to 650 mg/kg/day produced no adverse effects on the reproductive performance of parental animals or their progeny.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_B_ID_CFA6EA4C-BE25-4166-B308-C3EF97FE60BC"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy. Teratogenic Effects</h2>
<p class="First">PREGNANCY CATEGORY B</p>
<p>Oral reproduction studies in pregnant rats at doses up to 1500 mg/kg/day (9000 mg/m<span class="Sup">2</span>/day, 40.5 times the recommended human dose based on body surface area) and in pregnant rabbits at doses up to 275 mg/kg/day (3245 mg/m<span class="Sup">2</span>/day, 14.6 times the recommended human dose based on body surface area) have revealed no evidence of impaired fertility or harm to the fetus due to nizatidine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_EDE53204-CD9C-4460-BAC0-A38407EDFD58"></a><a name="section-6.6"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">Studies conducted in lactating women have shown that 0.1% of the administered oral dose of nizatidine is secreted in human milk in proportion to plasma concentrations. Because of the growth <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in pups reared by lactating rats treated with nizatidine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_36AD5CA4-774D-429A-AB27-783C2FC588DD"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_E429FE74-344F-4327-89A2-9A7636DF6EB9"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">Of the 955 patients in clinical studies who were treated with nizatidine, 337 (35.3%) were 65 and older. No overall differences in safety or effectiveness were observed between these and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold"><span class="Emphasis">DOSAGE AND ADMINISTRATION).</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_D3BBB1CF-E9AB-4278-84DB-A4563E385AF0"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Worldwide, controlled clinical trials of nizatidine included over 6,000 patients given nizatidine in studies of varying durations. Placebo-controlled trials in the United States and Canada included over 2,600 patients given nizatidine and over 1,700 given placebo. Among the adverse events in these placebo-controlled trials, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (0.2% vs 0%) and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (0.5% vs 0.1%) were significantly more common in the nizatidine group.</p>
<p><span class="Bold"><span class="Emphasis">Incidence in Placebo-Controlled Clinical Trials in the United States and Canada</span></span></p>
<p>Table 5 lists adverse events that occurred at a frequency of 1% or more among nizatidine-treated patients who participated in placebo-controlled trials. The cited figures provide some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the population studied.</p>
<p>Table 5</p>
<p>INCIDENCE OF TREATMENT-EMERGENT</p>
<p>ADVERSE EVENTS IN PLACEBO-CONTROLLED CLINICAL TRIALS</p>
<p>IN THE UNITED STATES AND CANADA</p>
<a name="ID_DD259114-9AB5-4168-9FBD-F05ABA3826B3"></a><table border="none" frame="void" width="405">
<col width="40.000%">
<col width="31.111%">
<col width="28.889%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"></td>
<td align="left" colspan="2" valign="top">Percentage of Patients Reporting Event</td>
</tr>
<tr>
<td align="left" valign="top">Body System/Adverse Event*</td>
<td align="left" valign="top">Nizatidine (N=2,694)</td>
<td align="left" valign="top">Placebo (N=1,729)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Body as a Whole</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left" valign="top">16.6</td>
<td align="left" valign="top">15.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="left" valign="top">7.5</td>
<td align="left" valign="top">12.5</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="left" valign="top">4.2</td>
<td align="left" valign="top">3.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="left" valign="top">3.1</td>
<td align="left" valign="top">2.9</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="left" valign="top">2.4</td>
<td align="left" valign="top">2.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td align="left" valign="top">2.3</td>
<td align="left" valign="top">2.1</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="left" valign="top">1.7</td>
<td align="left" valign="top">1.1</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="left" valign="top">1.6</td>
<td align="left" valign="top">2.3</td>
</tr>
<tr>
<td align="left" valign="top">Surgical Procedure</td>
<td align="left" valign="top">1.4</td>
<td align="left" valign="top">1.5</td>
</tr>
<tr>
<td align="left" valign="top">Injury, <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span></td>
<td align="left" valign="top">1.2</td>
<td align="left" valign="top">0.9</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Digestive</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left" valign="top">7.2</td>
<td align="left" valign="top">6.9</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left" valign="top">5.4</td>
<td align="left" valign="top">7.4</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="left" valign="top">4.9</td>
<td align="left" valign="top">5.4</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left" valign="top">3.6</td>
<td align="left" valign="top">5.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="left" valign="top">3.6</td>
<td align="left" valign="top">4.4</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="left" valign="top">2.5</td>
<td align="left" valign="top">3.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="left" valign="top">1.4</td>
<td align="left" valign="top">1.3</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left" valign="top">1.2</td>
<td align="left" valign="top">1.9</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="left" valign="top">1.2</td>
<td align="left" valign="top">1.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorder</span></td>
<td align="left" valign="top">1.1</td>
<td align="left" valign="top">1.2</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">Tooth disorder</span></td>
<td align="left" valign="top">1.0</td>
<td align="left" valign="top">0.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Musculoskeletal</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="left" valign="top">1.7</td>
<td align="left" valign="top">1.5</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Nervous</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="left" valign="top">4.6</td>
<td align="left" valign="top">3.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="left" valign="top">2.7</td>
<td align="left" valign="top">3.4</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></td>
<td align="left" valign="top">1.9</td>
<td align="left" valign="top">1.9</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="left" valign="top">1.9</td>
<td align="left" valign="top">1.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="left" valign="top">1.6</td>
<td align="left" valign="top">1.4</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="left" valign="top">1.1</td>
<td align="left" valign="top">0.8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Respiratory</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="left" valign="top">9.8</td>
<td align="left" valign="top">9.6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="left" valign="top">3.3</td>
<td align="left" valign="top">3.1</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="left" valign="top">2.4</td>
<td align="left" valign="top">2.1</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, increased</td>
<td align="left" valign="top">2.0</td>
<td align="left" valign="top">2.0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Skin and Appendages</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="left" valign="top">1.9</td>
<td align="left" valign="top">2.1</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="left" valign="top">1.7</td>
<td align="left" valign="top">1.3</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Special Senses</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span></td>
<td align="left" valign="top">1.0</td>
<td align="left" valign="top">0.9</td>
</tr>
</tbody>
</table>
<p>* Events reported by at least 1% of nizatidine-treated patients are included.</p>
<p>A variety of less common events were also reported; it was not possible to determine whether these were caused by nizatidine.</p>
<p><span class="Italics">Hepatic: </span><span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Hepatocellular injury</span>, evidenced by elevated liver enzyme tests (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> [AST], SGPT [ALT], or alkaline phosphatase), occurred in some patients and was possibly or probably related to nizatidine. In some cases there was marked elevation of <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT enzymes (greater than 500 IU/L) and, in a single instance, SGPT was greater than 2,000 IU/L. The overall rate of occurrences of elevated liver enzymes and elevations to 3 times the upper limit of normal, however, did not significantly differ from the rate of liver enzyme abnormalities in placebo-treated patients. All abnormalities were reversible after discontinuation of nizatidine. Since market introduction, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> have been reported. Rare cases of cholestatic or mixed hepatocellular and cholestatic injury with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> have been reported with reversal of the abnormalities after discontinuation of nizatidine.</p>
<p><span class="Italics">Cardiovascular: </span>In clinical pharmacology studies, short episodes of asymptomatic <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> occurred in 2 individuals administered nizatidine and in 3 untreated subjects.</p>
<p><span class="Italics">CNS: </span>Rare cases of reversible <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span> have been reported.</p>
<p><span class="Italics">Endocrine: </span>Clinical pharmacology studies and controlled clinical trials showed no evidence of antiandrogenic activity due to nizatidine. <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span> and decreased libido were reported with similar frequency by patients who received nizatidine and by those given placebo. Rare reports of <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> occurred.</p>
<p><span class="Italics">Hematologic: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> was reported significantly more frequently in nizatidine- than in placebotreated patients. Fatal <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was reported in a patient who was treated with nizatidine and another H<span class="Sub">2</span>-receptor antagonist. On previous occasions, this patient had experienced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> while taking other drugs. Rare cases of <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> have been reported.</p>
<p><span class="Italics">Integumental: </span><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> were reported significantly more frequently in nizatidine- than in placebo-treated patients. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> were also reported. <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span> has been reported rarely.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span>As with other H<span class="Sub">2</span>-receptor antagonists, rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> following administration of nizatidine have been reported. Rare episodes of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (eg, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>) have been reported.</p>
<p><span class="Italics">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span>-like reactions have occurred rarely in conjunction with nizatidine use.</p>
<p><span class="Italics">Genitourinary: </span>Reports of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have occurred.</p>
<p><span class="Italics">Other: </span><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> unassociated with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> or <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> was reported. <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> related to nizatidine administration have been reported.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_41738F4E-1DB2-4983-8A07-E7AB945C6851"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> of nizatidine have been reported rarely. The following is provided to serve as a guide should such an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> be encountered.</p>
<p><span class="Bold"><span class="Emphasis">Signs and Symptoms</span></span></p>
<p>There is little clinical experience with overdosage of nizatidine in humans. Test animals that received large doses of nizatidine have exhibited cholinergic-type effects, including <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Single oral doses of 800 mg/kg in dogs and of 1,200 mg/kg in monkeys were not lethal. Intravenous median lethal doses in the rat and mouse were 301 mg/kg and 232 mg/kg respectively.</p>
<p><span class="Bold"><span class="Emphasis">Treatment</span></span></p>
<p>To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the <span class="Italics">Physicians’ Desk Reference (PDR). </span>In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in your patient.</p>
<p>If overdosage occurs, use of activated charcoal, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, or lavage should be considered along with clinical monitoring and supportive therapy. The ability of hemodialysis to remove nizatidine from the body has not been conclusively demonstrated; however, due to its large volume of distribution, nizatidine is not expected to be efficiently removed from the body by this method.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_549D1D2D-E1ED-4E76-9478-9F38EC017B9D"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></span></span></p>
<p>The recommended oral dosage for adults is 300 mg once daily at bedtime. An alternative dosage regimen is 150 mg twice daily.</p>
<p><span class="Bold"><span class="Emphasis">Maintenance of Healed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></span></span></p>
<p>The recommended oral dosage for adults is 150 mg once daily at bedtime.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span></span></span></p>
<p>The recommended oral dosage in adults for the treatment of erosions, ulcerations, and associated <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> is 150 mg twice daily.</p>
<p><span class="Bold"><span class="Emphasis">Active Benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></span></span></p>
<p>The recommended oral dosage is 300 mg given either as 150 mg twice daily or 300 mg once daily at bedtime. Prior to treatment, care should be taken to exclude the possibility of malignant gastric ulceration.</p>
<p><span class="Bold"><span class="Emphasis">Dosage Adjustment for Patients With Moderate to Severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></span></p>
<p>The dose for patients with renal dysfunction should be reduced as follows:</p>
<p><span class="Bold"><span class="Emphasis">Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and Benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span></span></span></p>
<a name="ID_A771C4B8-014F-4102-B547-7E07CC0312BA"></a><table border="single" frame="box" width="442.8">
<col width="50.000%">
<col width="50.000%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Underline">Ccr</span></td>
<td align="center" valign="top"><span class="Underline">Dose</span></td>
</tr>
<tr>
<td align="center" valign="top">20-50 mL/min</td>
<td align="center" valign="top">150 mg daily</td>
</tr>
<tr class="Last">
<td align="center" valign="top">&lt;20 mL/min</td>
<td align="center" valign="top">150 mg every other day</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Emphasis">Maintenance Therapy</span></span></p>
<a name="ID_C6971789-A348-4904-9D4E-FFC2EAAB43D2"></a><table border="single" frame="box" width="442.8">
<col width="50.000%">
<col width="50.000%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Underline">Ccr</span></td>
<td align="center" valign="top"><span class="Underline">Dose</span></td>
</tr>
<tr>
<td align="center" valign="top">20-50 mL/min</td>
<td align="center" valign="top">150 mg every other day</td>
</tr>
<tr class="Last">
<td align="center" valign="top">&lt;20 mL/min</td>
<td align="center" valign="top">150 mg every 3 days</td>
</tr>
</tbody>
</table>
<p>Some elderly patients may have creatinine clearances of less than 50 mL/min, and, based on pharmacokinetic data in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the dose for such patients should be reduced accordingly. The clinical effects of this dosage reduction in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_EE375F7B-EDC5-414B-B5F1-4363FF936EBB"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Nizatidine capsules are available in:</p>
<p>The 150 mg capsule is a hard gelatin capsule with a <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow body and dark yellow cap. The body has “NZ 150? and the cap has “G?, both printed in black. They are available as follows:</p>
<p>Bottles of 60’s NDC 55567-109-16</p>
<p>Bottles of 100’s NDC 55567-109-18</p>
<p>Bottles of 500’s NDC 55567-109-25</p>
<p>Bottles of 1000’s NDC 55567-109-35</p>
<p>The 300 mg capsule is a hard gelatin capsule with a light brown body and cap. The body has “NZ 300? and the cap has “G?, both printed in black. They are available as follows:</p>
<p>Bottles of 30’s NDC 55567-110-13</p>
<p>Bottles of 50’s NDC 55567-110-15</p>
<p>Bottles of 500’s NDC 55567-110-25</p>
<p>Store at controlled room temperature, 15° to 30°C (59° to 86°F) (see USP).</p>
<p>Dispense in a tight container with a child-resistant closure.</p>
<p>Manufactured by:</p>
<p>Genpharm Inc.</p>
<p>Toronto, Canada</p>
<p>M8Z 2S6</p>
<p>Printed in Canada</p>
<p>007-775 REV.#02 October 2002</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NIZATIDINE 		
					</strong><br><span class="contentTableReg">nizatidine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55567-109</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Nizatidine</strong> (Nizatidine) </td>
<td class="formItem"></td>
<td class="formItem">150 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Yellow #10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Red #40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>pregelatinized starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>red iron oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>yellow iron oxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow and dark yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NZ;150;G</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55567-109-35</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55567-109-25</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55567-109-18</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55567-109-16</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NIZATIDINE 		
					</strong><br><span class="contentTableReg">nizatidine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55567-110</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Nizatidine</strong> (Nizatidine) </td>
<td class="formItem"></td>
<td class="formItem">300 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>pregelatinized starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>red iron oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>yellow iron oxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (light brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NZ;300;G</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55567-110-25</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55567-110-15</td>
<td class="formItem">50  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55567-110-13</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genpharm Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>A627B0C2-8861-62C3-DFA1-807168D85591</div>
<div>Set id: 9A148542-E478-422A-B8FB-88047C30534B</div>
<div>Version: 2</div>
<div>Effective Time: 20071129</div>
</div>
</div> <div class="DistributorName">Genpharm Inc.</div></p>
</body></html>
